PJP trims some of the volatility associated with biotech and specialty pharmaceuticals stocks with allocations to blue-chip pharmaceuticals names. For example, Dow components Pfizer (NYSE: PFE), Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK) combine for nearly 15% of the ETF’s weight.

However, if there is one thing PJP has recently become known for, aside from its stellar returns, it is being front-and-center in the pharmaceuticals industry consolidation. That theme, which has become increasingly prominent this year, has shined added light on the the $2.15 billion PJP, an ETF that recently celebrated its tenth anniversary. [Pharma ETFs Like Mylan-for-Perrigo News]

As home to companies such as Allergan (NYSE: AGN), Perrigo (NasdaqGS: PRGO) and Mylan (NYSE: MYL), among others, PJP is awash in specialty pharmaceuticals buyers and sellers. For the moment, PJP’s 24-stock lineup is probably littered more with buyers than sellers, the result of the ETF’s weights to the largest biotech stocks and the aforementioned blue-chip pharma names. However, several of PJP’s other holdings have been bandied about as potential targets.

PowerShares Dynamic Pharmaceuticals Portfolio

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.